Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Theragenics, Juniper Investment Company deal

Theragenics said it received a proposal from investment firm Juniper to acquire all outstanding shares of Theragenics for $2.25-$2.30 in cash, or about $70.7 million based on the midpoint of the range

Read the full 323 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE